Covance

Covance
Name	Covance
Type	Subsidiary
Industry	Pharmaceutical services
Founded	1996
Fate	Renamed after acquisition
Headquarters	Princeton, New Jersey, United States
Products	Drug development services, clinical trial management
Parent	LabCorp (since 2015)

Covance was a major contract research organization that provided preclinical, clinical, and laboratory testing services to pharmaceutical, biotechnology, and medical device companies. Founded in 1996 through a corporate restructuring, it became known for toxicology, bioanalytical testing, and central laboratory services supporting drug development and regulatory submissions. The company operated within the global pharmaceutical research ecosystem and was acquired by Laboratory Corporation of America in the mid-2010s.

History

Covance traces origins to businesses consolidated in the 1990s during a period of consolidation in the pharmaceutical services sector, following trends seen in mergers such as those involving GlaxoWellcome, SmithKline Beecham, and within companies like Quintiles and ICON plc. Early growth paralleled regulatory developments at agencies including the United States Food and Drug Administration and the European Medicines Agency, as demand expanded for preclinical safety studies and clinical trial management. In the 2000s the firm expanded through acquisitions and strategic partnerships with organizations such as Charles River Laboratories competitors and academic centers like Johns Hopkins University and University of Pennsylvania for translational research. The acquisition by Laboratory Corporation of America in 2015 integrated Covance into a larger diagnostics and services group, aligning it with other industry players like Quest Diagnostics and Bio‑Rad Laboratories.

Services and Operations

Covance provided a portfolio of services spanning preclinical studies, clinical development, and laboratory testing, similar in scope to offerings from Parexel International and PPD, Inc.. Preclinical toxicology and safety assessment programs were designed to meet standards used by regulators such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and to support filings under statutes like the Food, Drug, and Cosmetic Act. Clinical trial management included phase I-IV studies, pharmacokinetics and pharmacodynamics analysis, and central laboratory testing used in trials run by companies including Pfizer, Novartis, Roche, Eli Lilly and Company, and AstraZeneca. Bioanalytical services supported biomarker discovery collaborations with institutions such as Massachusetts General Hospital and Mayo Clinic. The company also offered manufacturing support and specialised services for biologics that paralleled capabilities at Genentech and Amgen.

Corporate Structure and Ownership

Originally established through corporate restructuring and spin‑offs, the company operated as an independent contract research organization before acquisition. Its corporate governance featured a board of directors and executive leadership interacting with shareholders, similar to governance structures at Johnson & Johnson and Merck & Co., Inc.. In 2015 the company was acquired by Laboratory Corporation of America in a deal that mirrored other industry consolidations involving firms such as Bristol-Myers Squibb and Thermo Fisher Scientific. Post-acquisition, integration efforts aligned operational units with divisions comparable to those at Siemens Healthineers and GE Healthcare.

Global Presence and Facilities

The organization maintained research sites, clinical laboratories, and support offices across North America, Europe, and Asia, akin to global footprints maintained by Coventry Health Care‑era contractors and multinational CROs such as ICON plc and Quintiles. Major laboratory complexes were located in regions with strong pharmaceutical clusters including New Jersey, California, the United Kingdom, Germany, India, and China. Facilities supported GLP toxicology studies, GCP clinical testing, and central laboratory operations used by sponsors like GlaxoSmithKline and Sanofi. The company’s operations interfaced with regional regulators, ethics committees, and institutional review boards such as those connected to Harvard Medical School and University College London.

Research and Development Contributions

Covance contributed to drug development pipelines by performing foundational toxicology, safety pharmacology, and bioanalytical work that enabled investigational new drug applications and marketing authorizations in therapeutic areas represented by companies like Bayer, Takeda Pharmaceutical Company Limited, Gilead Sciences, and Boehringer Ingelheim. Collaborations with academic centers and biotechs supported translational research in oncology, CNS disorders, and immunology, fields also advanced at institutions such as Dana-Farber Cancer Institute and Karolinska Institute. The company published technical reports, white papers, and method validations that informed practices used by peers such as Charles River Laboratories and regulatory reviewers at the Food and Drug Administration and European Medicines Agency.

Controversies and Criticism

Like other contract research organizations, the firm faced scrutiny over animal welfare practices in preclinical laboratories, drawing attention similar to controversies involving entities such as Brown University animal research debates and campaigns by People for the Ethical Treatment of Animals. Allegations and inspections touched on compliance with standards set by organizations like the Association for Assessment and Accreditation of Laboratory Animal Care International and national regulatory frameworks including those under the United States Department of Agriculture. The company also navigated legal and ethical challenges related to clinical trial conduct and data integrity, issues paralleled in high‑profile cases involving GlaxoSmithKline and Theranos‑era scrutiny, prompting internal policy reviews and third‑party audits. Post‑acquisition oversight by Laboratory Corporation of America and external regulators aimed to address compliance and transparency concerns.

Category:Contract research organizations Category:Pharmaceutical services companies